Consider the moment after a handshake. For most people, letting go requires no thought. For someone with myotonic dystrophy type 1, the muscle can struggle to relax. That delay makes an abstract phrase, “functional improvement,” rather concrete. Dyne Therapeutics is trying to build medicines that change such moments. To understand its wager, though, start somewhere smaller than the hand: the boundary of a muscle cell.
- The problem: a genetic medicine must reach the tissue where it needs to work.
- The approach: attach a therapeutic payload to an antibody fragment that recognizes a cellular receptor.
- The test: show that molecular changes produce durable benefits people can feel. Dyne’s medicines remain investigational.
The door before the drug
A useful instruction is useless at the wrong address. Dyne’s FORCE platform combines three components: an antigen-binding fragment, called a Fab; a linker; and a therapeutic payload. The Fab binds transferrin receptor 1, or TfR1, helping the attached medicine enter target cells. Different payloads can then perform different molecular jobs. Delivery becomes a reusable piece of the invention.
The distinction is physical as well as conceptual. Dyne uses a fragment rather than a full antibody. The company believes that smaller component can improve tissue penetration and tolerability while reducing immune activation. Those are proposed advantages, not a universal guarantee. The platform’s ambition extends to muscle and the central nervous system, with repeat dosing and longer intervals between treatments.
This puts Dyne inside the market for targeted genetic medicines, alongside other antibody-oligonucleotide developers. It also gives the company a precise question to answer: does its particular combination deliver enough useful medicine, safely, to the places that matter?
Three diseases, three jobs
In Duchenne muscular dystrophy, mutations prevent adequate production of dystrophin, a protein important to muscle integrity. Dyne’s lead candidate, zeleciment rostudirsen, previously DYNE-251, carries an exon-skipping payload. It is designed for people whose mutations are amenable to skipping exon 51. That eligibility condition matters: one candidate cannot serve the entire Duchenne population.
Sarepta’s Exondys 51 is an existing alternative for this mutation group. Dyne’s proposed difference is its delivery system. In December 2025, Dyne reported that the DELIVER registrational expansion cohort met its primary endpoint, reaching 5.46% of normal muscle content-adjusted dystrophin at six months. The trial was not powered to establish statistical significance on functional measures. Protein production and everyday ability remain connected questions requiring separate evidence.
Muscle content-adjusted level at six months in DELIVER’s registrational expansion cohort. Company-reported, December 2025.
For DM1, the job changes. Zeleciment basivarsen, previously DYNE-101, carries an antisense oligonucleotide designed to reduce toxic DMPK RNA in the nucleus and release proteins needed for normal RNA processing. For facioscapulohumeral muscular dystrophy, or FSHD, DYNE-302 instead carries an siRNA designed to suppress DUX4. The common delivery machinery does not erase the biological differences.
The programs also sit at different stages. Z-rostudirsen is under FDA Priority Review, with a January 21, 2027 target action date. Approval is pending. The DM1 program is in ACHIEVE and the confirmatory Phase 3 HARMONIA trial. DYNE-302 received clearance in July 2026 to begin a Phase 1 trial. A shared platform still needs a separate clinical case for each medicine.
For families following the pipeline, the practical first question is therefore the diagnosis and mutation, followed by the trial’s inclusion criteria. A program name is not an access pathway. Dyne’s patient materials point readers toward trial information; participation requires assessment against a specific study protocol.
The first stop sign
One early obstacle arrived before Dyne’s Duchenne candidate reached patients. In January 2022, the FDA placed its investigational application on clinical hold, asking for additional clinical and nonclinical information. This was a barrier to starting a trial, not a report that dosed patients had been harmed. In July, the agency lifted the hold and cleared the application.
The later evidence brought a different challenge: interpreting small groups. Dyne’s September 2026 DM1 update pooled 25-26 participants across several dose cohorts. The company reported improvements across measures, but only eight participants received the selected registrational dose throughout the full year analyzed. A mixed-dose analysis can support a hypothesis without settling it. The larger registrational cohort and confirmatory trial are where that hypothesis faces a tougher examination.
This is also why the company’s results deserve careful reading. A comparison with a matched natural-history group asks a different question from a randomized placebo comparison. Matching can improve comparability, but it does not make the two designs interchangeable. The distinction affects how much confidence a reader should place in an encouraging number.
A very expensive route to ordinary life
Dyne was incorporated in 2017 and incubated by Atlas Venture. Scientist and co-founder Romesh Subramanian helped shape the company; Jason Rhodes served as founding president and CEO. The public launch came in 2019 with $50 million in Series A financing. A roughly $268 million gross IPO followed in 2020. These were payments for the chance to develop medicines, not evidence of medicine sales.
The distinction remains essential. Dyne’s model is to develop proprietary therapies and, if approved, commercialize them. In July 2026 it raised approximately $431.4 million gross through another public offering. Research and development expense alone reached $152.2 million in the second quarter. That quarterly figure measures development spending, not the cost of one program or a future patient’s bill.
Its intended users are people with genetically defined diseases. Today, access depends on clinical-trial eligibility. A future commercial business would also need prescribers, manufacturing capacity and reimbursement. John Cox, appointed CEO in March 2024, brought experience in rare-disease commercialization. Getting through a cell membrane and getting a medicine to a patient are different delivery problems.
“One mission, no ego.”
A published Dyne core value
CureDuchenne Ventures adds another perspective to the financing history. Its 2020 investment connected the company to an organization whose constituency lives with the disease. Capital and community knowledge arrived in the same relationship.
The part worth borrowing
Dyne calls its employees Dynamos. A more useful cultural detail is its use of patient advisory boards and trial-design workshops. Families supply something a molecular diagram cannot: a description of which changes would make daily life easier. That makes listening part of product development.
The lesson for other builders is an inference, not a clinical claim: find the step that keeps a useful invention from reaching its user. Build around that bottleneck. Reuse what genuinely transfers, then test each application independently. Dyne’s approach depends on adequate delivery, tolerable dosing and convincing benefit. Mutation mismatches, inadequate exposure or disappointing confirmatory results would limit it. The meaningful destination remains the same: a person doing something that disease had made difficult.